Impact of the 2018 revised Pregnancy Prevention Programme by the European Medicines Agency on the use of oral retinoids in females of childbearing age in Denmark, Italy, Netherlands, and Spain: an interrupted time series analysis

Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women.Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisa...

Повний опис

Бібліографічні деталі

Автори:	Carlos E. Durán, Judit Riera-Arnau, Shahab Abtahi, Romin Pajouheshnia, Vjola Hoxhaj, Magdalena Gamba, Ema Alsina, Mar Martin-Perez, Patricia Garcia-Poza, Ana Llorente-Garcia, Diana Gonzalez-Bermejo, Luisa Ibánez, Mònica Sabaté, Xavier Vidal, Elena Ballarín, Gabriel Sanfélix-Gimeno, Clara Rodríguez-Bernal, Salvador Peiró, Aníbal García-Sempere, Francisco Sanchez-Saez, Valentina Ientile, Ylenia Ingrasciotta, Claudio Guarneri, Matilde Tanaglia, Michele Tari, Ron Herings, Eline Houben, Karin Swart-Polinder, Emily Holthuis, Consuelo Huerta, Rosa Gini, Giuseppe Roberto, Claudia Bartolini, Olga Paoletti, Giorgio Limoncella, Anna Girardi, Giulia Hyeraci, Morten Andersen, Sarah Brøgger Kristiansen, Christine Erikstrup Hallgreen, Olaf Klungel, Miriam Sturkenboom
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2023-08-01
Серія:	Frontiers in Pharmacology
Предмети:	oral retinoids isotretinoin contraceptive measures dermatologic conditions acne risk minimisation measures
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1207976/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!